Pharmacy Workforce

ASHP Announces Phase I Results of 2024 Pharmacy Residency Match

Published: March 13, 2024
Match Day 2024

Pharmacy Graduates Continue to Seek Postgraduate Training to Advance Patient Care Skills

The ASHP (American Society of Health-System Pharmacists) announced today 4,916 individuals matched with 2,200 pharmacy residency programs across the country in Phase I of ASHP's 2024 Pharmacy Residency Match.

The Phase I results include an early commitment of 664 postgraduate year 1 (PGY1) residents who accepted a PGY2 position at their current program. With 5,872 residency positions in the Match, 956 positions remain available to be filled in Phase II.

“Congratulations to all of the student pharmacists and residents who matched with pharmacy residencies this year,” said Samuel V. Calabrese, BSPharm, MBA, FASHP, CPEL, vice president of the ASHP Office of Accreditation Services. “We are thrilled to see the sustained enthusiasm for the invaluable clinical learning experiences provided by postgraduate residency training. Residency candidates continue to pursue this training as a direct result of the ongoing efforts by program directors and preceptors to spotlight the value these programs have for the profession. ASHP looks forward to supporting the development of the new class of trainees.”

Interest in postgraduate residency training continues to grow, with more than 46% of enrolled fourth-year pharmacy students applying for residency positions. Early commitments for PGY2 positions increased by 10%, and applications to PGY2 also grew.

ASHP’s upcoming national public awareness campaign aims to inform consumers about pharmacy practice in hospital and health-system settings and the value pharmacists bring to patient care. The campaign aims to build interest in hospital and health-system practice careers and foster additional growth in postgraduate training.

The Match also continued steady growth in the number of available residency positions. The number of positions has grown from 5,312 in 2020 to 5,872 (including early commits), a 10% growth in positions.


ASHP conducts the Match in two phases. The deadline to register to participate in Phase II of the Match is April 2, 2024. The informal post-match scramble will be held following Phase II of the Match to ensure that individuals have as many chances as possible to connect with a residency program. 

ASHP provides several resources to guide applicants in navigating the Match process, including advice for Phase II of the Match, interview tips, and more. National Matching Services Inc. administers and conducts the Match and provides an overview of the 2024 ASHP Residency Match process.

About ASHP
ASHP is the largest association of pharmacy professionals in the United States, representing 60,000 pharmacists, student pharmacists, and pharmacy technicians in all patient care settings, including hospitals, ambulatory clinics, and health-system community pharmacies. For over 80 years, ASHP has championed innovation in pharmacy practice, advanced education and professional development, and served as a steadfast advocate for members and patients. In addition, ASHP is the accrediting body for pharmacy residency and technician training programs and provides comprehensive resources to support pharmacy professionals through every stage of their careers. For more information, visit and ASHP’s consumer website,

Posted March 13, 2024

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information